Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air (XAIR) reported Q2 FY2026 results. Revenue was $1.8 million, up from $0.8 million a year ago, but cost of revenues of $2.1 million produced a gross loss of $0.3 million. Operating expenses were $7.4 million, leading to a loss from operations of $7.7 million and a net loss of $8.3 million (basic and diluted loss per share $1.25).
Cash, cash equivalents, marketable securities and restricted cash totaled $10.9 million as of September 30, 2025. The company raised $8.1 million via its ATM program and received $2.9 million from warrant exercises during the six months. Long‑term debt, net, was $10.1 million, and management disclosed that recent results and projected cash outflows raise “substantial doubt” about the ability to meet obligations without additional financing.
The LungFit PH leasing business recognized $1.4 million in revenue in the quarter, and minimum future lease payments contracted total $11.1 million through 2029. Shares outstanding were 8,009,488 as of November 7, 2025; this is a baseline figure, not the amount being offered.
Beyond Air (XAIR) reported an insider equity update: a director’s outstanding stock options were repriced by the board to an exercise price of $1.95 per share, effective November 4, 2025. The new price matches the closing price on November 3, 2025, and all other terms, including vesting, remain unchanged under the company’s Amended and Restated 2013 Equity Incentive Plan.
The filing lists multiple option grants adjusted from prior exercise prices of $10.80 and $5.892 to $1.95, with representative tranches of 10,000, 4,500, 2,000, 1,500, and 1,250 options now reflecting the revised strike price.
Beyond Air, Inc. (XAIR) director reported warrant transactions on Form 4. In connection with a $2,000,000 loan to the company, the reporting person acquired warrants to purchase up to 512,821 shares at $1.95. Separately, an outstanding warrant for 494,332 shares at $7.586 was cancelled and a replacement warrant for 494,332 shares at $1.95 was issued. The warrants are exercisable on or after issuance and expire five years from their respective issuance dates.
Beyond Air, Inc. (XAIR) disclosed a director Form 4 reflecting a board-approved option repricing. On November 4, 2025, the board reduced the exercise price of certain outstanding stock options to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025.
The Form 4 shows multiple option awards previously carrying exercise prices of $10.80 and $5.892, each adjusted to $1.95. The company states that all other terms of the options remain unchanged. These options were granted under the Amended and Restated 2013 Equity Incentive Plan and continue to follow their existing vesting schedules, subject to the director’s continued service.
Beyond Air (XAIR) reported insider activity on a Form 4 detailing an option repricing for its Chief Financial Officer effective November 4, 2025. The exercise price of certain stock options was reduced to $1.95 per share, the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.
The filing shows cancellations of options previously priced at $10.80 and $5.892 and grants at $1.95 in equivalent amounts, including 15,000, 6,000, 3,750, 1,000, and 17,500 options. Following the reported transactions, the CFO beneficially owns 47,500 derivative securities directly. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and will vest per the original award agreements, subject to continued service.
Beyond Air, Inc. (XAIR) reported a Form 4 showing an option repricing approved by its Board on November 4, 2025. The exercise price of certain director stock options was reduced to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.
The filing reflects paired transactions where options previously carrying a $10.80 exercise price were disposed and corresponding options with a $1.95 exercise price were acquired. Table entries include examples of 187 option units repriced per line item. The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest as previously reported, subject to the reporting person’s continued service.
Beyond Air (XAIR) filed a Form 4 disclosing an option repricing for its CEO and Chairman, Steven A. Lisi. The Board approved an adjustment effective November 4, 2025, reducing the exercise price of multiple existing stock option grants to $1.95 per share, which the filing states was the closing price on November 3, 2025. All other terms of the options remain unchanged.
The Form 4 lists several grant lots that were modified, including blocks such as 47,500 and 40,000 options that previously carried higher exercise prices like $10.80 and $5.892 per share. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest per their original schedules, contingent on continued service.
Beyond Air (XAIR) director reported an option repricing. On November 4, 2025, multiple stock option grants were repriced to an exercise price of $1.95 per share, effective the same day. The filing shows cancellations of prior options at higher strike prices (including $10.80 and $5.892) and corresponding grants at $1.95 for the same share amounts.
The company states that all other terms of the options remain unchanged. These awards were issued under the Amended and Restated 2013 Equity Incentive Plan and remain subject to the existing vesting schedules and the reporting person’s continued service.
Beyond Air (XAIR) disclosed an insider derivative change by CEO and Chairman Steven A. Lisi. On 11/03/2025, he canceled 164,778 warrants with a $7.586 exercise price and received a replacement warrant for 164,778 shares at $1.95. The warrant was originally issued on September 27, 2024, became exercisable on November 22, 2024, and will expire five years from November 22, 2024. Following these transactions, he directly holds 164,778 warrants.
Beyond Air (XAIR) announced new financing and equity arrangements. The company entered an equity purchase agreement with Streeterville Capital for up to $20,000,000 in common stock, subject to a resale registration becoming effective and while no balance remains on a related note. The company agreed to file the registration statement by November 24, 2025. Share sales are bounded by a 4.99% Beneficial Ownership Limitation and Nasdaq’s 19.99% cap unless stockholder approval or pricing conditions under Rule 5635(d) are met.
Beyond Air also issued a secured promissory note with a principal amount of $12,050,000, receiving net proceeds of $12,000,000. The note matures in 24 months, carries 15% annual interest with no accrual for the first 12 months, and guarantees $1,800,000 of interest. Collateral includes a $6,000,000 cash DACA via a new subsidiary, with step-down mechanics as principal is repaid.
The company amended a prior loan to add a $2,000,000 term loan and issued five-year warrants to purchase 512,821 shares at $1.95, while repricing certain 2024 warrants to $1.95. Separately, 726,618 employee and director stock options were repriced to $1.95.